曲妥珠单抗-美坦新偶联物
| 中文名称 | 曲妥珠单抗-美坦新偶联物 |
|---|---|
| 中文同义词 | 曲妥珠单抗-美坦新偶联物 (TDM-1);曲妥珠单抗-EMTANSINE偶联物;曲妥珠单抗-美坦新偶联物;Trastuzumab emtansine试剂;Trastuzumab emtansine (anti-ERBB2);恩美曲妥珠单抗 |
| 英文名称 | Trastuzumab emtansine |
| 英文同义词 | Ado-trastuzuMab-eMtansine cas nr;trastuzumab emtansine;Ado-trastuzumab Emtansine (TDM-1);PRO132365;trastuzumab-DM1;trastuzumab-MCC-DM1;trastuzumab-MCC-DM1 antibody-drug conjugate;Trastuzumab emtansine (ADC) |
| CAS号 | 1018448-65-1 |
| 分子式 | |
| 分子量 | 0 |
| EINECS号 | |
| 相关类别 | 医药原料 |
| Mol文件 | Mol File |
| 结构式 |
曲妥珠单抗-美坦新偶联物 性质
| 储存条件 | Store at -20°C |
|---|---|
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
Trastuzumab emtansine (Ado-Trastuzumab emtansine) 是一种抗体偶联药物 (ADC)，其结合了 HER2 靶向的曲妥珠单抗的抗肿瘤特性以及微管抑制剂 DM1 的细胞毒活性。Trastuzumab emtansine 可用于晚期乳腺癌的研究。
Trastuzumab emtansine (2 μg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells.
Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice.
| Animal Model: | CB-17/SCID mice (6 weeks) were injected with OVA10 cells |
| Dosage: | 15 mg/kg |
| Administration: | I.v. three to five times weekly for 3 weeks |
| Result: | Showed remarkable inhibition of tumor growth in mice and was well tolerated. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-P9921A | 曲妥珠单抗-美坦新偶联物 Trastuzumab emtansine (solution) | 1018448-65-1 | 1 mg | 4800元 |
| 2026/06/05 | HY-P9921 | 曲妥珠单抗-美坦新偶联物 Trastuzumab emtansine | 1018448-65-1 | 1mg | 4800元 |